Eli Lilly sued AIOS/Fella Health over compounded tirzepatide and corporate-practice-of-medicine allegations.
SourceAccelerating the global take-up of GLP-1 medications
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Aios Medical (doing business as Fella Health and Bolt Pharmacy) is a San Francisco-based, founder-led consumer-health and telehealth company building ClinicOS, an AI-powered clinical operating system for direct-to-patient healthcare. It started with male-focused GLP-1 weight-loss care and now uses that stack across its own brands.
Primary product
Male-focused medication weight-loss telehealth program (Fella Health) powered by ClinicOS
Founded
2021
Headquarters
San Francisco, California, United States
Team size
51-200
Work style
Flexible
Industry
Medical Practices
Sub-industry
Telehealth / consumer health / weight-loss medicine
13 jobs at Aios Medical
Business model
Stage
seed
Total raised
$130K
Latest round
Seed · Jan 2021
Latest amount
$130K
Jan 2021 · BrandProject
Leadership
CEO & Co-founder
VP Growth
Head of Product
Gzim Helshani
Head of Engineering
Joy I.
Business Operations Lead
Stanley W.
Customer Success Lead
Jamie B.
Lifecycle Marketing Lead
Marjoe Bacus
Lead Designer
Dave Lane
Founding Head of Growth
Nick S.
Paid Media Lead
Founders
Co-founder
Investors
Founder-led, intense, and highly performance-oriented. Public hiring materials emphasize a Day 1 mentality, fast experimentation, remote/async work, and long days/weekends for senior roles.
Work style
Flexible
Compensation
Public job posts show salary-plus-equity compensation across a wide range: senior remote roles around $125k-$400k base plus equity/percent upside, UK clinical roles around £75k-£150k plus equity, and fractional clinical roles around CAD$60-$90/hour plus equity.
Benefits
Pricing
Monthly subscription / membership with medication included on some plans; some products are sold as separate monthly treatments, and UK branded-drug fulfillment is offered at cost.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$250M-$500M
Estimated monthly visits
134.2K
Traffic estimate as of Jul 2026
Eli Lilly sued AIOS/Fella Health over compounded tirzepatide and corporate-practice-of-medicine allegations.
SourceFDA shortage enforcement and the end of mass compounded GLP-1 access tightened the market for Fella and peers.
SourceAIOS acquired UK pharmacy Bolt Pharmacy and used it to reaccelerate growth after the US compounding crackdown.
SourceSTAT · Apr 2025
STAT described the end of mass compounded GLP-1 access after FDA shortage enforcement, a major operating shift for telehealth vendors like Fella.
CNBC · Apr 2025
Lilly sued four telehealth companies including Fella Health over compounded tirzepatide, alleging deceptive marketing and unauthorized versions of its obesity drugs.
STAT · Apr 2025
STAT reported that Lilly’s new lawsuits targeted corporate practice of medicine theories, including claims involving Fella Health.
The New York Times · Apr 2024
The New York Times covered Fella’s male-focused marketing of weight-loss drugs and the broader 'brozempic' trend.